

Attorney's Docket No. 1543.004 (5784-81)

Handwritten: #21. 1/10/02
Signature: [illegible]
PATENT

RESPONSE UNDER 37 C.F.R. 1.116 - EXPEDITED
PROCEDURE - EXAMINING GROUP 1653

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(NE)

In re: Whitehouse

Appl. No.: 09/385,114

Filed: August 27, 1999

For: ANGIOGENICALLY EFFECTIVE UNIT DOSE OF FGF-2
AND METHOD OF USE

Group Art Unit:

1653

Examiner:

Hope Robinson

January 7, 2002

Box AF

Commissioner for Patents

Washington, DC 20231

**AMENDMENT AFTER FINAL ACTION
PURSUANT TO 37 C.F.R. § 1.116**

Sir:

Responsive to the Office Action mailed September 7, 2001, Applicant respectfully requests reexamination and reconsideration of the above-referenced application in view of the following amendments and remarks. The Examiner is respectfully requested to enter the following amendments.

In the Claims:

Please amend claim 38 as follows:

38. (amended) The method of claim 10, wherein said therapeutically effective amount of said recombinant FGF-2 or said angiogenically active fragment or mutein thereof is administered by infusion.

Handwritten: Please enter 3/23/02

01/10/2002 09:11:34 00000001 130605 09385114

RTA01/2109349v1 110.00 CP